Reported prevalence varies widely across studies, from roughly 11% to 88% depending on the population and cause studied, but the underlying tissue change is consistent: rapid stretching causes microscopic tearing in the dermis, disrupting the organised collagen and elastin structure that gives skin its integrity. This is histologically similar to a scar, not a surface pigmentation issue, which is why the same category of remodelling-focused ingredients gets proposed for both.

Stretch marks progress through two distinct stages, and this distinction matters more than most stretch mark marketing acknowledges.

A specific "2009 placebo-controlled study" showing copper peptides significantly improve stretch marks circulates widely across skincare marketing content. We could not independently verify that this study exists. What we did find is a genuinely comprehensive review of the topical stretch mark literature.

The same review's broader conclusion is worth stating plainly: even the best-studied topical stretch mark treatments (tretinoin, silicone gel) have limited, inconsistent evidence, and no topical has been shown to eradicate stretch marks. This isn't a category where any product, including ours, can honestly claim a solved problem.

GHK-Cu's case for stretch marks rests entirely on extrapolation from its documented role in wound healing and dermal matrix remodelling, the same logic covered in more depth in our article on GHK-Cu and scarring. Stretch marks and scars share the same core problem: disorganised or depleted collagen, elastin, and glycosaminoglycans in the dermis. GHK-Cu's documented mechanism addresses exactly that.

These papers establish GHK-Cu's documented mechanism in tissue remodelling, largely in wound models rather than stretch marks specifically. They support biological plausibility, not a demonstrated clinical outcome for striae.

Across the topical treatments that have actually been studied for stretch marks, a consistent pattern holds: active, still-remodelling striae rubrae respond more reliably than mature, comparatively inert striae albae. Tretinoin, the most-studied topical in this space, showed genuine improvement in rubrae across multiple trials but limited or no effect on albae. This pattern reflects general tissue biology, not anything specific to any one ingredient.

It's reasonable to expect GHK-Cu would follow the same general pattern, since its mechanism depends on stimulating cells that are still active enough to respond to remodelling signals. But that's an inference from how stretch mark biology and other topicals have behaved in studies, not a finding from a GHK-Cu stretch mark trial, because that trial doesn't appear to exist yet.

If you're going to try 1% GHK-Cu Face and Skin Serum on stretch marks, apply it consistently to the affected area, generally once or twice daily, and set a realistic evaluation window. Dermal remodelling is slow regardless of the active involved; our general guidance on how long before you see results and our GHK-Cu long-term use article both point to a minimum of 8-12 weeks before assessing whether a remodelling-focused active is doing anything, and stretch marks, being a deeper structural change than surface texture, should be judged on the longer end of that range.

If you're pregnant or trying to prevent stretch marks during pregnancy specifically, see our dedicated article on GHK-Cu safety during pregnancy and breastfeeding before starting, as that carries its own separate evidence gaps worth understanding first.

This article is provided for educational purposes and does not constitute medical advice. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition. If you are pregnant or breastfeeding, consult a qualified healthcare professional before use.

AmpleLab.